Procurement Sciences Closes $30 Million Series B to Accelerate AI Platform Helping Businesses Find, Win and Deliver Government Contracts

Backed by Catalyst Investors, Battery Ventures and strategic partners, the companyextends its leadership with the first AI-native operating system for GovCon,transforming how businesses compete in the $1 trillion public sector market Procurement Sciences, the AI software company transforming how businesses find, win and deliver on government contracts, today announced it has closed $30 million in […]

Calico Life Sciences Announces U.S. FDA Orphan Drug Designation for Investigational Treatment of Autosomal Dominant Polycystic Kidney Disease

Calico Life Sciences LLC (Calico), a biotechnology organization focused on aging and age-related diseases and founded by Alphabet Inc. and Arthur D. Levinson, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ABBV-CLS-628, an investigational therapy for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). ABBV-CLS-628,

Discover Holiday Magic Across Pierce County’s Hidden Corners

Your guide to winter wonder in the mountain towns and small communities of Pierce County Visit Tacoma-Pierce County invites you to unwrap the season with the Holiday Magic Calendar, a handpicked collection of festive experiences tucked into the charming corners of Pierce County. From snow-dusted foothill towns to cozy fireside inns, this is the ultimate

Satsuma Pharmaceuticals and SNBL Announce Publication of Impression of Use and Satisfaction with STS101 (Dihydroergotamine Nasal Powder (Atzumi™)) in Headache

Results show that participant impression through 12 months of treatment indicate STS101 is perceived as favorable across multiple attributes. Exploratory Efficacy Endpoints showed that STS101 provided rapid freedom from pain, from most bothersome symptoms at 2 hours and sustained treatment benefits over 48 hours after dosing. Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company and its

Verismo Therapeutics to Announce Upcoming Presentations at SITC and ASH Annual Meetings

Verismo Therapeutics, a clinical-stage CAR T company developing a novel KIR-CAR platform technology, today announced its participation at the upcoming Society of Immunotherapy in Cancer (SITC) 2025 Annual Meeting and American Society of Hematology (ASH) 2025 Annual Meeting. The company will present new preclinical and translational data supporting the advancement of its clinical pipelines, SynKIR™-110

NYU Jonathan Tisch Center of Hospitality, Stayntouch, and IDeaS Release 2026 Hotel Technology Outlook Report

New research reveals key trends shaping hotel technology investment, satisfaction, and strategy, and a clear shift toward Best-in-Class integrated systems over All-in-One platforms. The NYU School of Professional Studies Jonathan M. Tisch Center of Hospitality(NYU SPS Tisch Center), in collaboration with Stayntouchand IDeaS Revenue Solutions, today released a new industry report, 2026 Hotel Technology Outlook:

Paramount and PBR Announce Landmark Five-Year Media Rights Deal

Paramount+ to Become Streaming Home of PBR Unleash The Beast Paramount and PBR (Professional Bull Riders) today announced a new five-year media rights agreement that will make Paramount+ the primary streaming home of PBR's premier tour, Unleash The Beast, starting in the 2026 season beginning December 12. Under the agreement, Paramount+ will stream live coverage

93rd Annual Brunswick Veterans Day Parade Scheduled for November 9, 2025

City's Annual Celebration Is One of Oldest Veterans Day Events in the Nation The City of Brunswick is proud of its history and patriotism, which can be witnessed on Nov. 9, as the city hosts its 93rd annual Brunswick Veterans Day Parade, making this event one of the oldest of its kind in the country.

Ardmore Shipping Corporation Announces Financial Results For The Three and Nine Months Ended September 30, 2025

Ardmore Shipping Corporation (NYSE: ASC) (“Ardmore”, the “Company” or “we”) today announced results for the three and nine months ended September 30, 2025. Highlights and Recent Activity — Reported Adjusted earnings of $12.6 million and net income attributable to common stockholders of $12.1 million for the three months ended September 30, 2025, or $0.31 Adjusted

MCO (MyComplianceOffice) Brings Compliance Leaders Together at MCO Exchange 2025

Two-Day Event Connected Compliance Professionals from Leading Financial Services Firms to Share Best Practices, Explore MyComplianceOffice Enhancements, and Shape the Future of Regulatory Technology MCO (MyComplianceOffice), a leading provider of integrated compliance technology solutions, successfully hosted its MCO Exchange 2025 user conference. The customer-focused event brought together compliance professionals, industry leaders, and MCO experts for

Scroll to Top